Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25928360 | 0.91 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2USP2TSHRRXFP1 | |
| SCHEMBL23921110 | 0.72 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2TSHRRXFP1 | |
| SCHEMBL25927206 | 0.71 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2USP2TSHRRXFP1 | |
| SCHEMBL23920922 | 0.71 | PNP (0.38) | ALDH1A1USP2TSHRRXFP1 | |
| SCHEMBL21396428 | 0.68 | PDE4A (0.31) | — | |
| SCHEMBL23921064 | 0.67 | ALDH1A1 (0.40) | ALDH1A1USP2TSHRRXFP1 | |
| SCHEMBL25928193 | 0.66 | PNP (0.37) | ALDH1A1USP2TSHR | |
| SCHEMBL21396518 | 0.65 | ADORA2A (0.39) | — | |
| SCHEMBL23921210 | 0.63 | CYP3A4 (0.40) | ALDH1A1USP2TSHRRXFP1 | |
| SCHEMBL25927975 | 0.63 | CYP3A4 (0.38) | ALDH1A1USP2TSHRRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | ALDH1A1 3952/4885SMN1; SMN2 4500/4885USP2 3345/4885 |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PDE7A | ALDH1A1 3981/4885SMN1; SMN2 4506/4885USP2 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.